| Project/Area Number |
25460213
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
Suno Manabu 岡山大学, 医療教育統合開発センター, 准教授 (20621189)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAGASAKA Takeshi 岡山大学, 病院, 講師 (30452569)
KITAMURA Yoshihisa 岡山大学, 病院, 准教授 (40423339)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | トラマドール / 光学異性体 / 遺伝子多型 / CYP2D6 / LC-MSMS |
|---|
| Outline of Final Research Achievements |
CYP2D6, tramadol metabolism related enzymes, has polymorphisms. In this study, plasma concentrations of tramadol measured and, examined the plasma concentration changes of tramadol and occurrence of side effects in cancer pain patients. As a result, the plasma concentration of tramadol in patients with CYP2D6 intermediate metabolizer was higher than that in patients with CYP2D6 extensive metabolizer. Assessment of side effects, as headaches, nausea and vomiting, were observed on high frequency in the CYP2D6 intermediate metabolizer patients after tramadol administration 7 days. These finding suggests that considering the CYP2D6 polymorphism can be effectiveness and safely use for tramadol in cancer pain patients.
|
